Compare Vanguard Mega Cap Growth ETF (MGK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs TransMedics Group Inc — how do they compare? Vanguard Mega Cap Growth ETF trades at $94.42 (market cap $33.70B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 12.3× TransMedics Group Inc's market cap, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and TransMedics Group Inc for 24 Days on average.
| MGK | TMDX | |
|---|---|---|
Market Cap | $33.70B | $2.74B |
Volume | 1,362,010 | 949,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $150.42 |
52-Week Low | $70.70 | $61.99 |
Typical Hold Time | 45 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Morningstar Mega Cap Growth ETF, trades at $94.42, down 0.53% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides exposure to large-cap U.S. growth stocks like Nvidia and Apple, with a low expense ratio of 0.05% (Vanguard, 2026-07-18). Recent news highlights its strong five-year returns and suitability for long-term growth investors.
The outlook for MGK is positive, driven by its concentrated mega-cap growth holdings and cost efficiency, though risks include tech sector volatility and market concentration. Analyst sentiment is favorable, emphasizing its role in growth portfolios for investors seeking higher returns with manageable risk.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
